Ketryx and Accenture Build Regulated AI MedTech at Scale
Ketryx and Accenture are combining AI-native compliance infrastructure and transformation expertise to help MedTech scale regulated AI without slowing development.
Regulated AI is creating a new challenge for MedTech. How do companies increase development speed without multiplying compliance risk?
Ketryx and Accenture are addressing that gap through a partnership that combines continuous compliance infrastructure with enterprise transformation and adoption expertise. The partnership reflects a wider shift toward compliance embedded directly into regulated product development.
AI Increases the Volume Of Regulatory Evidence
AI can accelerate software development, testing, documentation, and product iteration. It can also increase the number of changes that Quality and Regulatory teams must assess.
That creates a structural problem for MedTech. Engineering velocity can increase much faster than the capacity to review, validate, document, and trace every change.
Traditional processes often rely on teams assembling evidence after development work has taken place.
Requirements, risks, code, tests, and design records may sit across different systems, making traceability dependent on manual reconciliation.
The regulatory environment leaves little room for weak links.
IEC 62304 establishes software lifecycle processes for medical device software, while ISO 14971 covers risk management across the medical device lifecycle.
U.S. Food and Drug Administration (FDA) guidance on AI-enabled device software also takes a total product lifecycle approach, covering development, deployment, maintenance, and performance management.
For MedTech developers scaling AI across multiple products, the issue is therefore not simply whether AI can generate more output.
It’s whether the organisation can generate more good evidence to support regulatory compliance at the same pace.
Maximise Pharma Innovation With Quality-by-Design
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
Ketryx And Accenture Are Combining Two Different Capabilities
The Ketryx and Accenture partnership brings together complementary roles.
Accenture will lead transformation activities, including strategy, process redesign, and organisational adoption. Its MedTech practice already positions intelligent technologies, including generative AI and predictive analytics, as part of broader digital transformation.
Accenture says 97% of MedTech chief executives it surveyed believe generative AI will transform their company and industry.
Ketryx provides the compliance infrastructure underneath those changes.
According to Ketryx, its platform connects development workflows to continuous traceability, automated documentation, validation, and regulatory processes.
The company says its platform is used by four of the top five Fortune 500 MedTech companies, while its reported customer outcomes include up to 90% less documentation time and release cycles more than 10 times faster. These are company-reported figures, not independent industry benchmarks.
Partnering the two roles matters immensely.
Technology can provide the infrastructure and transformation determines whether an organisation actually changes how it works.
That is arguably the more important element of the partnership.
Continuous Compliance Changes the Model
The deeper innovation is not another documentation tool but the vision to make compliance part of the development system itself.
Ketryx describes an approach in which requirements, development activity, testing, risk management, and regulatory evidence remain connected as products evolve.
Its newer AI capabilities extend this model through agentic workflows designed to automate selected compliance activities while retaining human review for safety-critical decisions.
This direction aligns with the FDA’s increasing focus on lifecycle management for AI-enabled medical devices. The agency’s draft guidance recommends considering AI throughout design, development, deployment, maintenance, and performance management, rather than treating regulatory evidence as a single submission-stage activity.
The development model therefore shifts from:
Build → document → reconcile → validate → submit
to:
Build → capture evidence → assess → review → release
This is important as AI generates more frequent product changes.
The infrastructure also creates a potential advantage for change management. If a requirement, design element, risk control, or test changes, connected records can help identify which downstream artefacts may require review.
The value is not eliminating regulatory oversight but reducing the manual work required to demonstrate that oversight has happened.
A Partnership for MedTech Transformation
The Ketryx-Accenture partnership is significant because it treats regulated AI as more than a software procurement decision.
While the immediate partnership centres on MedTech, the underlying challenge extends across regulated life sciences: AI adoption creates more activity, more outputs, more decisions, and therefore more evidence that must remain trustworthy and compliant.
Pharmatica's analysis of AI in GMP manufacturing examines a similar issue in pharmaceutical operations: AI can improve monitoring and decision support, but adoption depends on validation, data integrity, governance, and human oversight.
The same principle applies to regulatory infrastructure. Analysis of digital CMC submissions explores how structured digital evidence could reduce fragmentation between manufacturing activity and regulatory processes.
For MedTech, the most important questions for the future of AI are clear:
- Can compliance evidence be generated as work happens?
- Can AI-assisted workflows remain validated and auditable?
- Can Quality and Regulatory teams scale without simply adding headcount?
- Can engineers work faster without creating documentation debt?
- Can organisations preserve accountable human oversight as AI adoption expands?
The Ketryx and Accenture model suggests the answer may require both technology and organisational change.
The Looming Threat of Geopolitical Risk in Clinical Supply Chains
Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.
Regulated AI Needs More Than Faster Development
The Ketryx and Accenture partnership envisions moving compliance from being a checkpoint to rather being part of the tech infrastructure.
That could prove increasingly important as regulated product development becomes more software-driven, AI-assisted, and continuous.
At Pharmatica, we analyse the technologies and operating models shaping regulated life sciences. Our focus is where AI, regulation, and product development intersect, helping decision-makers understand not just what is changing, but what it means for the organisations responsible for delivering safe products.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What is regulated AI?
Regulated AI refers to artificial intelligence used within products, processes, or environments subject to regulatory requirements. In MedTech, this can include AI-enabled medical devices and software where organisations must demonstrate safety, effectiveness, appropriate risk management, validation, and ongoing lifecycle control.
Why is AI compliance important in MedTech?
AI can increase the speed and volume of product development, but regulated companies must still demonstrate that products are safe, effective, and appropriately controlled. AI compliance connects development activity with the evidence required for regulatory and quality oversight. The FDA’s AI-enabled device guidance takes a total product lifecycle approach to these considerations.
How does continuous compliance support AI development?
Continuous compliance embeds evidence generation, traceability, validation, and controls into development workflows rather than leaving documentation until the end of a project. This approach can help teams identify gaps earlier and maintain evidence as products change.
What is AI validation in medical device development?
AI validation is the process of establishing documented evidence that an AI-related system or workflow performs as intended within its defined use and regulatory context. For AI-enabled medical devices, validation must be considered alongside lifecycle management, risk, performance, and appropriate documentation. The FDA also provides specific recommendations for predetermined change control plans that support planned AI modifications.
Can AI automate regulatory compliance in MedTech?
AI and automation can support parts of regulatory compliance, including traceability, documentation, testing workflows, impact assessment, and evidence management. Automation does not remove the need for human accountability or regulatory oversight. The objective is to reduce repetitive compliance work while strengthening the systems used to control and demonstrate product quality.
About the author
Did you enjoy the content?
Why not support Nicole Dale by giving this content a like
Comments (0)